July 7 (Reuters) - Alnylam Pharmaceuticals Inc

* Alnylam and Sanofi Genzyme initiate ATLAS phase 3 program with investigational RNAi therapeutic fitusiran


* Says expect top-line data from the ATLAS trials in mid-to-late 2019

* says ATLAS studies are expected to enroll about 250 patients across 3 separate trials conducted around the world


* Says ATLAS to evaluate safety and efficacy of Fitusiran across broad spectrum of patients living with hemophilia Source text for Eikon: Further company coverage: